Citadel Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $58.8M | Buy |
112,400
+7,500
| +7% | +$3.58M | 0.01% | 1206 |
|
|
2025
Q4 | $61.1M | Buy |
104,900
+41,100
| +64% | +$21M | 0.01% | 1247 |
|
|
2025
Q3 | $29.3M | Buy |
63,800
+16,000
| +33% | +$5.97M | ﹤0.01% | 1898 |
|
|
2025
Q2 | $14.5M | Sell |
47,800
-20,700
| -30% | -$6.17M | ﹤0.01% | 2561 |
|
|
2025
Q1 | $22.7M | Sell |
68,500
-16,900
| -20% | -$5.55M | ﹤0.01% | 1900 |
|
|
2024
Q4 | $26.4M | Buy |
85,400
+31,800
| +59% | +$8.94M | ﹤0.01% | 1876 |
|
|
2024
Q3 | $11.4M | Sell |
53,600
-3,400
| -6% | -$870K | ﹤0.01% | 2712 |
|
|
2024
Q2 | $16M | Sell |
57,000
-53,700
| -49% | -$12.8M | ﹤0.01% | 2238 |
|
|
2024
Q1 | $29.6M | Buy |
110,700
+45,800
| +71% | +$10.8M | 0.01% | 1676 |
|
|
2023
Q4 | $15M | Buy |
64,900
+2,100
| +3% | +$367K | ﹤0.01% | 2337 |
|
|
2023
Q3 | $9.17M | Sell |
62,800
-55,100
| -47% | -$10.4M | ﹤0.01% | 2799 |
|
|
2023
Q2 | $27.2M | Buy |
117,900
+52,700
| +81% | +$14.3M | 0.01% | 1578 |
|
|
2023
Q1 | $15.8M | Sell |
65,200
-186,900
| -74% | -$50.9M | ﹤0.01% | 2205 |
|
|
2022
Q4 | $73.2M | Buy |
252,100
+158,000
| +168% | +$15.5M | 0.02% | 835 |
|
|
2022
Q3 | $6.12M | Buy |
94,100
+37,800
| +67% | +$2.63M | ﹤0.01% | 3542 |
|
|
2022
Q2 | $4.03M | Buy |
56,300
+36,000
| +177% | +$2.65M | ﹤0.01% | 4195 |
|
|
2022
Q1 | $1.99M | Sell |
20,300
-21,700
| -52% | -$1.83M | ﹤0.01% | 6090 |
|
|
2021
Q4 | $3.56M | Sell |
42,000
-25,100
| -37% | -$2.06M | ﹤0.01% | 4986 |
|
|
2021
Q3 | $5.35M | Buy |
67,100
+28,300
| +73% | +$2.44M | ﹤0.01% | 4170 |
|
|
2021
Q2 | $3.78M | Sell |
38,800
-5,400
| -12% | -$639K | ﹤0.01% | 5053 |
|
|
2021
Q1 | $5.17M | Buy |
44,200
+14,000
| +46% | +$1.63M | ﹤0.01% | 4183 |
|
|
2020
Q4 | $3.36M | Sell |
30,200
-9,500
| -24% | -$1.16M | ﹤0.01% | 4387 |
|
|
2020
Q3 | $4.71M | Buy |
39,700
+2,600
| +7% | +$282K | ﹤0.01% | 3254 |
|
|
2020
Q2 | $4.2M | Buy |
37,100
+21,900
| +144% | +$2.15M | ﹤0.01% | 3332 |
|
|
2020
Q1 | $1.01M | Buy |
15,200
+1,000
| +7% | +$83.3K | ﹤0.01% | 5314 |
|
|
2019
Q4 | $1.29M | Buy |
14,200
+6,100
| +75% | +$592K | ﹤0.01% | 5131 |
|
|
2019
Q3 | $698K | Sell |
8,100
-27,600
| -77% | -$2.59M | ﹤0.01% | 6197 |
|
|
2019
Q2 | $3.74M | Sell |
35,700
-55,300
| -61% | -$5.92M | ﹤0.01% | 3509 |
|
|
2019
Q1 | $11.4M | Sell |
91,000
-44,800
| -33% | -$5.57M | 0.01% | 1910 |
|
|
2018
Q4 | $15.3M | Buy |
135,800
+74,200
| +120% | +$11.5M | 0.01% | 1456 |
|
|
2018
Q3 | $13.2M | Buy |
61,600
+40,300
| +189% | +$10.1M | 0.01% | 1797 |
|
|
2018
Q2 | $5.96M | Buy |
+21,300
| New | +$3.74M | ﹤0.01% | 2535 |
|
|
2016
Q2 | – | Sell |
-500
| Closed | -$4K | – | 7159 |
|
|
2016
Q1 | $4K | Sell |
500
-529
| -51% | -$4.42K | ﹤0.01% | 6629 |
|
|
2015
Q4 | $13K | Buy |
1,029
+192
| +23% | +$5.27K | ﹤0.01% | 8172 |
|
|
2015
Q3 | $51K | Sell |
837
-57
| -6% | -$4.11K | ﹤0.01% | 7567 |
|
|
2015
Q2 | $70K | Buy |
894
+168
| +23% | +$14.1K | ﹤0.01% | 7415 |
|
|
2015
Q1 | $49K | Sell |
726
-271
| -27% | -$23.2K | ﹤0.01% | 7393 |
|
|
2014
Q4 | $92K | Buy |
997
+160
| +19% | +$16.5K | ﹤0.01% | 6711 |
|
|
2014
Q3 | $88K | Buy |
837
+3
| +0.4% | +$417 | ﹤0.01% | 6521 |
|
|
2014
Q2 | $119K | Sell |
834
-380
| -31% | -$55.5K | ﹤0.01% | 6089 |
|
|
2014
Q1 | $183K | Buy |
1,214
+48
| +4% | +$9.45K | ﹤0.01% | 5604 |
|
|
2013
Q4 | $214K | Sell |
1,166
-154
| -12% | -$28.2K | ﹤0.01% | 4957 |
|
|
2013
Q3 | $292K | Sell |
1,320
-363
| -22% | -$77.2K | ﹤0.01% | 4378 |
|
|
2013
Q2 | $294K | Buy |
+1,683
| New | +$439K | ﹤0.01% | 4316 |
|
Other funds holding MDGL
BBA
RI
ACA
PC
VPM
VCM
Citadel Advisors's MDGL Position: Q1 2026 in Review
Citadel Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 1,156% in Q1 2026, buying an estimated $200M and bringing the position to 453,843 shares worth $238M. The position accounts for 0.04% of the portfolio, ranked #381.
Citadel Advisors first reported a position in MDGL in Q2 2013 and has held it in 48 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.
- Citadel Advisors held 453,843 shares of Madrigal Pharmaceuticals worth $238M as of Q1 2026.
- Citadel Advisors bought 417,709 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $200M.
- Madrigal Pharmaceuticals made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #381 holding.
- Citadel Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
- 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.